QCG
AMLX icon

Quadrant Capital Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

Quadrant Capital Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5
Closed -$108 – 2686
2023
Q2 		$108 Sell
5
-7
-58% -$189 ﹤0.01% 2674
2023
Q1 		$353 Buy
+12
New +$417 ﹤0.01% 2634

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Quadrant Capital Group's AMLX Position: Q3 2023 in Review

Quadrant Capital Group sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2023, closing a stake of 5 shares — an estimated $108 sold.

Quadrant Capital Group first reported a position in AMLX in Q1 2023 and held it in 2 quarters. The position peaked at $353 in Q1 2023. 170 funds tracked by Wall St. Rank hold AMLX as of Q3 2023.

  • Quadrant Capital Group reported no remaining Amylyx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 5 Amylyx Pharmaceuticals shares in Q3 2023, an estimated $108.
  • Quadrant Capital Group first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Quadrant Capital Group's Amylyx Pharmaceuticals position peaked at $353 in Q1 2023.
  • 170 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2023.

Based on Quadrant Capital Group's 13F filing for Q3 2023, filed 14 Nov 2023.